Lifestance Health Group, INC

LifeStance Health Group announces immediate resignation of director Jeffrey Rhodes and appoints three new board members, Thurman Justice, Lori Goltermann, and Safwan Shabab.

LifeStance Health Group, Inc. reports the successful election of directors and ratification of auditors at its 2026 annual meeting.

LifeStance Health Group, Inc. has entered into an underwriting agreement for the sale of 35 million shares of common stock by selling stockholders.

LifeStance Health Group, Inc. announced an underwritten secondary offering of 25 million common shares by selling stockholders, with the company repurchasing 7 million of those shares.

LifeStance Health Group announced robust fourth quarter and full year 2025 financial results, including double-digit revenue growth and positive net income, alongside a new $100 million share repurchase program.

LifeStance Health Group, a leading mental healthcare provider, announced record third-quarter 2025 financial results, including positive net income and raised full-year guidance.

LifeStance Health Group, Inc. announced significant revenue increases and improved operational metrics for the second quarter of 2026, alongside ongoing efforts to address internal control deficiencies.

LifeStance Health Group, Inc. reported a return to net income in the third quarter of 2025 with a 16% revenue increase, despite ongoing material weaknesses in internal financial controls.

LifeStance Health Group, Inc. reported an 11% revenue increase and significantly reduced its net loss for the second quarter and first half of 2025, driven by clinician hiring and patient visit growth.

LifeStance Health Group's Q1 2025 shows revenue growth of 11% year-over-year, but material weaknesses in internal controls persist.

LifeStance Health Group's Q3 2024 results show a 19% year-over-year increase in total revenue, driven by growth in patient visits and modest payor rate increases.

LifeStance Health Group, a national outpatient mental health provider, announced a 20% increase in revenue for the second quarter of 2024, driven by clinician growth and patient visits, while still reporting a net loss.

LifeStance Health Group, Inc. reported a significant financial turnaround in 2025, achieving net income and positive operating income, driven by strong revenue growth and increased patient visits.

LifeStance Health Group's 2024 10-K filing reveals a year of growth amidst regulatory complexities, strategic realignments, and ongoing efforts to improve internal controls.

LifeStance Health Group's 2023 10-K filing details its financial performance, growth strategies, and risk factors, highlighting its position as a major outpatient mental health platform.

Teresa Deluca, a Director of LifeStance Health Group, Inc., sold 20,441 shares of common stock on August 13, 2026 for $12.23 per share.

Kenneth A Burdick, a Director of LifeStance Health Group, Inc., sold 500,000 shares of common stock on August 11, 2026 for $11.51 per share.

Vukasin Paunovich, Chief Technology Officer of LifeStance Health Group, Inc., sold 44,394 shares of common stock on August 10, 2026 for $10.85 per share.

Tpg Gp A, Llc and 2 others reported changes in beneficial ownership of LifeStance Health Group, Inc. common stock on August 10, 2026.

Lisa K Miller, Chief Operating Officer of LifeStance Health Group, Inc., sold 47,912 shares of common stock on August 10, 2026 for $10.85 per share.

Kenneth A Burdick, a Director of LifeStance Health Group, Inc., received 45,495 shares of common stock on July 6, 2026.

LifeStance Health Group, Inc. has released its 2026 proxy statement detailing director elections, executive compensation, and the ratification of its independent auditor.

LifeStance Health Group will hold its annual stockholders meeting virtually on June 3, 2025, to vote on director elections, auditor ratification, and executive compensation.

LifeStance Health Group will hold its annual stockholders meeting virtually on June 3, 2025, to vote on director elections, auditor ratification, and executive compensation.

LifeStance Health Group will hold its annual meeting of stockholders on June 3, 2024, to vote on director elections, auditor ratification, executive compensation, and other business.

LifeStance Health Group will hold its annual stockholders meeting virtually on June 3, 2024, to vote on director elections, auditor ratification, executive compensation, and other business matters.

TPG GP A, LLC, along with James G. Coulter and Jon Winkelried, have jointly filed an amendment to Schedule 13G, reporting a combined beneficial ownership of 98,101,407 shares of LifeStance Health Group, Inc. common stock, representing 25.7% of the outstanding shares.

Summit Partners, through various affiliated entities, has updated its beneficial ownership filing for LifeStance Health Group, Inc., reporting a combined 6.10% stake.

TPG GP A, LLC and its principals report a 29.3% beneficial ownership stake in LifeStance Health Group, Inc. via an amended Schedule 13G filing.

Summit Partners and its affiliated entities have filed an amendment to their Schedule 13G, disclosing a 7.49% beneficial ownership in LifeStance Health Group, Inc.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 12.0% beneficial ownership stake in LifeStance Health Group Inc. common stock as of December 31, 2025.

Summit Partners and its affiliated entities have filed an amended Schedule 13G, reporting a collective beneficial ownership of 8.62% in LifeStance Health Group, Inc.